Skip to the main content.

Cell and Gene Therapy Series. Part 3 - Clusters, Megadeals, "Cellicon Valley" and the "Golden Triangle

Dr. Dave Seaward : 28 February 2022

Cell and Gene Therapy Series. Part 3 - Clusters, Megadeals,

In this third instalment to our cell and gene blog series, author Dave Seaward explains where most ATMP technology is being delivered as well as providing insight into why.

Click here to gain an understanding of why investors believe significant returns will be made from these technologies.
How our robotic isolator technology is setting a new standard for aseptic fill-finish

How our robotic isolator technology is setting a new standard for aseptic fill-finish

David Johnson: 15 April 2026

In the world of pharmaceutical manufacturing, our robotic isolator technology sets a new standard for aseptic fill-finish technology. By integrating...

Read More
Key Factors to Consider During the Design Process in Aseptic Manufacturing

Key Factors to Consider During the Design Process in Aseptic Manufacturing

David Johnson: 13 April 2026

Demand for the design and development of specialist aseptic manufacturing solutions is being driven by the significant growth in biological drug...

Read More
How patent expirations will reshape the Dry Powder Inhaler (DPI) Market?

How patent expirations will reshape the Dry Powder Inhaler (DPI) Market?

Tom Bailey: 13 April 2026

Over the next few years, a wave of patent expirations for leading inhaled therapies will fundamentally change the Dry Powder Inhaler (DPI) market....

Read More